
The Blood Matters program aims to support and enhance best practice in patient blood management (PBM), and the stewardship of blood and blood products, for improved patient outcomes in Victorian health services.
What's new
-
The 2020-21 Serious Transfusion Incident Reporting (STIR) system annual report and summary report are now available on the STIR page.
Visit the Serious Transfusion Incident Reporting system page.
-
SCV have released a news statement from Adjunct Professor Stephen Cornelissen, Australian Red Cross Lifeblood Chief Executive, regarding the increased demand for blood, and the challenges to support the use of group O RhD negative RBC in Australia.
The National Blood Authority, and national stakeholders, are preparing a National Statement for the Emergency Use of Group O RBC, which includes the use of group O RhD positive RBC. The statement can be found via the page Demand for blood products on the Safer Care Victoria website.
Please take the time to read the statement and consider your health services emergency use of blood group O RBC.
-
The festive season is fast approaching, and once again it is time for us to consider how we can keep blood wastage to a minimum over this period.
Donated blood is a precious gift, and we all need to do our part to protect and manage this valuable resource. Let’s celebrate the donor’s precious gift this festive season.
For more information, see the webpage blood component .
-
Details of storage requirements for all SCIg products can be found on the SCIg program tools and resources page.
These tools and resources include:
SCIg program - clinical guidance version 11- September 2022SCIg program - Getting started presentation pptxSCIg program - getting started presentation -
Read about the recent changes to the reporting definitions from some STIR categories.
Visit the Serious Transfusion Incident Reporting page.
-
The manufacturing process for five of Australia’s domestic plasma products will change.
The products will continue to be manufactured in Australia from Australia’s plasma, but will be manufactured using CSL Behring’s global manufacturing processes.
As per the current products, the transitioned products will comply with the safety and efficacy requirements set by the Therapeutic Goods Administration. For more information visit the National Blood .
-
In 2022 Blood Matters will conduct a two-part consent audit:
- Part A is a blood transfusion consent policy reviewÂ
- Part B is a retrospective medical record audit of up to 30 patients. These patients received a blood component transfusion.Â
The audit will be open from 27 June to 12 August.
Audit instructions and data collection tools are available from the Blood Matters  page.
-
The Australian and New Zealand Society of Blood Transfusion (ANZSBT) and the Royal Australian College of Physicians (RACP) have developed a Top-Five Recommendations on low-value . This is useful guidance for clinical transfusion practice.
The Serious Transfusion Incident Reporting (STIR) annual report and summary report 2019-20 are now available.
Reviewed 06 December 2022